Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00403416
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2006-11-22
Brief Title:
Efficacy and Safety of AEB071 Plus Tacrolimus Converted to Mycophenolic Acid After 3 Months in Renal Transplant Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
12-month Open Label Randomized Multicenter Study Evaluating Efficacy Safety and Tolerability of Oral AEB071 Plus Tacrolimus Converted to Mycophenolic Acid After 3 Months vs Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the efficacy and safety of AEB071 in preventing acute rejections after kidney transplantation when combined with tacrolimus for the first 3 months and with myfortic thereafter
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None